This study found a marked reduction in vaccine serotype carriage after PCV7 implementation. The overall pneumococcal, H. influenzae and S. aureus carriage decreased slightly, but not significantly.
This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
The European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC) have published the second joint EU report on antimicrobial resistance in zoonotic bacteria affecting humans, animals and food.
The European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC) have published their annual report on zoonoses and food-borne outbreaks in the European Union for 2010.
Despite a reduction in pertussis among younger children and infants, rates of pertussis-related sickness and death remain high compared with rates for other vaccine-preventable diseases in England and Wales.
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine.
Starting 15 September 2011, ECDC will be coordinating the former EUVAC.NET network. It is a surveillance network covering measles, mumps, rubella, congenital rubella, pertussis and varicella EU Member States and three countries of the European Economic Area. Data will be hosted by the European Surveillance System (TESSy) at ECDC.
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.